Kymera Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018
Market Capitalization	2,065	1,413	1,369	3,263	2,756	-	-
Market Cap Growth	-	3.16%	-58.03%	18.36%	-	-	-
Enterprise Value	1,742	1,117	973	2,832	2,477	-73	-41
PE Ratio	-9.61	-9.61	-8.85	-32.55	-50.44	-	-
PS Ratio	25.93	17.98	29.25	44.80	80.99	-	-
PB Ratio	5.16	3.58	2.79	7.10	9.71	-	-
P/FCF Ratio	-10.29	-10.29	-8.78	-24.99	34.88	-	-
P/OCF Ratio	-13.74	-13.74	-8.95	-25.30	31.28	-	-
EV/Sales Ratio	22.17	14.21	20.79	38.88	72.77	-24.72	-
EV/EBITDA Ratio	-7.80	-7.80	-6.42	-29.00	-56.65	1.80	1.91
EV/EBIT Ratio	-7.61	-7.61	-6.30	-28.31	-54.46	1.76	1.89
EV/FCF Ratio	-8.13	-8.13	-6.24	-21.69	31.34	-4.18	2.11
Debt / Equity Ratio	0.21	0.21	0.04	0.04	0.06	-0.28	-0.02
Debt / EBITDA Ratio	-0.59	-0.59	-0.11	-0.18	-0.41	-0.52	-0.03
Debt / FCF Ratio	-0.62	-0.62	-0.11	-0.14	0.23	1.22	-0.04
Quick Ratio	4.62	4.62	5.79	4.85	2.70	2.71	8.83
Current Ratio	4.73	4.73	5.88	4.88	2.73	2.69	8.92
Asset Turnover	0.14	0.14	0.08	0.14	0.11	0.04	-
Interest Coverage	-748.81	-748.81	-878.59	-571.67	-395.46	-895.65	-1340.69
Return on Equity (ROE)	-34.80%	-34.80%	-33.80%	-27.20%	-52.20%	75.80%	-
Return on Assets (ROA)	-25.30%	-25.30%	-26.60%	-18.70%	-18.10%	-51.30%	-
Return on Capital (ROIC)	-34.51%	-34.51%	-31.78%	-21.05%	-15.34%	79.31%	63.58%
Earnings Yield	-7.21%	-10.40%	-11.30%	-3.07%	-1.98%	-	-
FCF Yield	-6.74%	-9.72%	-11.39%	-4.00%	2.87%	-	-
Buyback Yield / Dilution	-8.22%	-8.22%	-12.39%	-176.60%	-921.45%	9.44%	-
Total Shareholder Return	-8.22%	-8.22%	-12.39%	-176.60%	-921.45%	9.44%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).